ER

AdventHealth Opening New Off-Site Emergency Department in Winter Haven

Retrieved on: 
Thursday, May 9, 2024
HuntonBrady, Florida State Road 540, Hospital, Legoland, Partnership, Garden, HAVEN, Patient, AdventHealth, Multimedia, Tourism

WINTER HAVEN, Fla., May 9, 2024 /PRNewswire/ -- Hospital leaders, local government officials and members of the business community took the next step in bringing better access to high-quality emergency care to Winter Haven with the ribbon-cutting ceremony for the new AdventHealth Winter Haven ER on Thursday, May 9, 2024.

Key Points: 
  • The AdventHealth Winter Haven ER has 24 exam rooms, including a resuscitation room, a bariatric room, an isolation room, obstetrics-friendly room and pediatric-friendly rooms.
  • The AdventHealth Winter Haven ER marks the first phase of our commitment to expanding emergency care in Winter Haven.
  • The AdventHealth Winter Haven project is just the latest in the longtime partnership between AdventHealth and Robins & Morton.
  • The AdventHealth Winter Haven ER, a department of AdventHealth Heart of Florida, will open to new patients by the end of May 2024.

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 9, 2024
PFS, Sale, FDA, Azacitidine, Cancer, Research and development, Investment, ZF, IST, Nausea, Research, Hematology, KICKSTART, Fulvestrant, Insurance, AML, Artificial intelligence, Administration, ZFA, Science, Vomiting, COX, Patient, Fatigue, MNK, Effector, G&A, Assistant, Messenger, Acute myeloid leukemia, Cell, Interval (mathematics), Associate, Therapy, NSCLC, Breast cancer, Anemia, Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses were $5.3 million for the quarter ended March 31, 2024, compared to $6.6 million for the same quarter of 2023.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.1 million for the quarter ended March 31, 2024, compared to $2.9 million for the same quarter of 2023.
  • G&A expenses included approximately $0.6 million and $0.7 million of non-cash stock compensation expense in the quarters ended March 31, 2024, and 2023, respectively.
  • Other Expense: Other expense was $0.4 million and $0.5 million for the quarters ended March 31, 2024, and 2023, respectively.

Knight Therapeutics Reports First Quarter 2024 Results

Retrieved on: 
Thursday, May 9, 2024
Knight, DLBCL, News, ITP, Health maintenance organization, Hot, Vaginal discharge, Depreciation, Thrombocytopenia, Stomach, Inventory, Collection, Trial of the century, ASCT, Lymphoma, Patient, Acquisition, VVA, IAS, Menopause, Lenalidomide, Absorption, Blue balls, Bookkeeping

Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.

Key Points: 
  • Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.
  • Accounts payable and accrued liabilities: As at March 31, 2024, accounts payable and accrued liabilities were $94,711, an increase of $4,094 or 5%.
  • Cash, cash equivalents and marketable securities: As at March 31, 2024, Knight had $181,859 in cash, cash equivalents and marketable securities, an increase of $20,034 or 12% compared to December 31, 2023.
  • Knight will host a conference call and audio webcast to discuss its first quarter ended March 31, 2024, today at 8:30 am ET.

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Investment, Webcast, IND, WFS1, TDP43, AMX0035, Diabetes, Samuel, CSF, Biomarker, Astellas Pharma, Disclosure, Brain, Food, Amylyx Pharmaceuticals, Endoplasmic reticulum, Health Canada, Tauopathy, ALS, Eli Lilly and Company, FCCP, Medication, Merck, Cerebrospinal fluid, Safety, PB, Neurological disorder, Genetic linkage, Week, Wolfram syndrome, C-peptide, DSM-IV codes, Drug development, Clinical trial, Walking, Division, MD, Patient, Disease, Regulation Fair Disclosure, Principal, Regulation, PGIC, Metabolism, Interim, FACP, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.
  • This decision was informed by topline PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community.
  • Amylyx anticipates reporting topline data from all 12 participants at Week 24 in the fall of 2024.
  • Amylyx’ management team will host a conference call and webcast today, May 9, 2024, at 8:00 a.m.

New Perspective Senior Living Expands SafelyYou, Adopts Breakthrough SafelyYou Clarity™, Reduces Fall-related ER Visits to Incredible 2.8%

Retrieved on: 
Tuesday, May 7, 2024
Seniors, Managed Care, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, Consumer, Partnership, Management

They expanded based on the success they saw with the company, combined with the introduction of SafelyYou’s industry-changing innovation, SafelyYou Clarity™.

Key Points: 
  • They expanded based on the success they saw with the company, combined with the introduction of SafelyYou’s industry-changing innovation, SafelyYou Clarity™.
  • Clarity enables operators to align labor to care plans, better meeting residents’ needs and making the most of staffing resources.
  • For senior living communities, this means erring on the side of caution and leveraging emergency services.
  • SafelyYou means unnecessary ER visits are reduced—and communities can reduce fall-related ER send outs—like the astonishing 2.8% of ER visits resulting from falls at New Perspective communities.

Interviews Available: Mother/Daughter, Mother/Son and Father/Son Nurse Duos Call Providence Mission Hospital Home

Retrieved on: 
Monday, May 6, 2024
ICU, Friends, Patient, Nursing, Family, Parent, Hospital, Infant, SICU

The parents on each team have worked at the hospital for decades and inspired their children to join the nursing ranks.

Key Points: 
  • The parents on each team have worked at the hospital for decades and inspired their children to join the nursing ranks.
  • Kris is a spine/brain critical care nurse; went back-to-school to become a nurse when Kayla was a baby.
  • Kayla was born at Mission Hospital and grew up answering the phones in the ICU where she now works.
  • Jessica, known as her mom's twin, worked at Mission Hospital in high school; she is an ICU nurse that shares patients with her mom.

CHEAPCARIBBEAN IS GIVING AWAY 50 FREE VACATIONS TO HEROES IN HONOR OF NURSES' AND TEACHERS' APPRECIATION WEEK

Retrieved on: 
Monday, May 6, 2024
Travel, Teacher, Nursing, RIU, Sand, Tourism

NEW YORK, May 6, 2024 /PRNewswire/ -- CheapCaribbean Vacations is providing a prescription for sun, sand and a heavy dose of fun in celebration of Nurses Appreciation Week (May 6-12) and Teacher Appreciation Week (May 6-10). For teachers and nurses only, fold up the scrubs and power down the projectors as the travel booking site known for its Caribbean travel packages is offering 50 teachers and nurses from across the country the chance to win a three-night stay at their choice of any participating RIU Resort. With everything available at the property from dining, daily activities, nightly entertainment, limitless libations and more, this is the perfect way to swap code-blues and late-night grading sessions for margaritas and peaceful golden hours.

Key Points: 
  • NEW YORK, May 6, 2024 /PRNewswire/ -- CheapCaribbean Vacations is providing a prescription for sun, sand and a heavy dose of fun in celebration of Nurses Appreciation Week (May 6-12) and Teacher Appreciation Week (May 6-10).
  • "In celebration of Nurses' and Teachers' Appreciation Week we are thrilled to launch a nationwide giveaway for the heroes across the country who dedicate their time to helping others," says Dana Studebaker, Vice President of Marketing, Consumer Brands, ALG Vacations.
  • RIU operates all-inclusive resorts in destinations such as Aruba, Bahamas, Costa Rica, Jamaica, Panama, Mexico and Dominican Republic.
  • All healthcare professionals and teachers can score $150 off their next vacay by signing up for the ER&R and Beach4Teach Clubs.

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Friday, May 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Friday, May 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Jefferson Health Establishes the Stephen and Sandra Sheller Consult and Bridge Program to Provide Person-Centered Care for People with Substance Use Disorder

Retrieved on: 
Thursday, May 2, 2024
Family, Public health, Patient, Food, Jefferson Health, Ecosystem, Opioid use disorder, Risk, Housing, Health, The Pew Charitable Trusts, Substance use disorder, FAAFP, Buprenorphine, Methadone, Thomas Jefferson University, Master of Science, Physician, Bridge program, Sheller, Pew, FACP, MPP, Nursing

PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Today, Jefferson Health announced the opening of the Stephen and Sandra Sheller Consult and Bridge Program. The Bridge Program is an ecosystem of coordinated, high-quality care for people with severe substance use disorder. In this model, a single interdisciplinary care team provides comprehensive services for the Bridge patients across community, hospital, emergency department, and psychiatry settings. In addition to the full spectrum of health needs, the program's staff assists patients with social needs such as housing, legal assistance, and food insecurity. The Stephen and Sandra Sheller Consult Bridge Program serves as a vital safe harbor for patients in the earliest stages of medical and substance use recovery.

Key Points: 
  • The Bridge Program is an ecosystem of coordinated, high-quality care for people with severe substance use disorder.
  • The Stephen and Sandra Sheller Consult Bridge Program serves as a vital safe harbor for patients in the earliest stages of medical and substance use recovery.
  • The Bridge Program is an ecosystem of coordinated, high-quality care for people with severe substance use disorder
    "Jefferson Health is committed to creating innovative new programs for delivering compassionate, person-centered care.
  • "We enthusiastically chose Jefferson Health to be the recipient of our foundation funds for this new Stephen and Sandra Sheller Consult and Bridge Program.